Associated Papers
Kufor-Rakeb syndrome-associated psychosis: a novel loss-of-function ATP13A2 variant and response to antipsychotic therapy.
Colijn MA et al.
Neurogenetics, 2024
Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H+,K+-ATPase.
Fujii T et al.
Nature Communications, 2023
Conformational cycle of human polyamine transporter ATP13A2.
Mu J et al.
Nature Communications, 2023
37031211 (PubMed )
Supplement: 41467_2023_37741_MOESM1_ESM.pdf
ATP13A2 (PARK9) and basal ganglia function.
Croucher KM et al.
Frontiers in Neurology, 2023
Frequency of Parkinson's Disease Genes and Role of PARK2 in Amyotrophic Lateral Sclerosis: An NGS Study.
Vacchiano V et al.
Genes, 2022
35893043 (PubMed )
Supplement: genes-13-01306-s001.zip › genes-1768203-supplementary.pdf
Rodent models based on endolysosomal genes involved in Parkinson's disease.
Sanchiz-Calvo M et al.
Current Opinion in Neurobiology, 2022
Structural basis of polyamine transport by human ATP13A2 (PARK9).
Sim SI et al.
Molecular Cell, 2021
ATP13A2 deficiency disrupts lysosomal polyamine export.
van Veen S et al.
Nature, 2020
α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G et al.
Neurobiology of Disease, 2015
Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.
Covy JP et al.
Journal of Neuroscience Research, 2012
Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism.
Podhajska A et al.
Plos One, 2012
Select a paper to view details